The Committee for Medicinal Products for Human Use of the European Medicine Agency has adopted a positive opinion for the extension of the marketing authorization of Adcetris (brentuximab vedotin) and recommended its approval in combination with doxorubicin, vinblastine, and dacarbazine—or AVD—in adult patients with previously untreated CD30+ stage 3 Hodgkin lymphoma.
Cancer survivorship in the United States now tops 18 million people. That is a lot of people walking around with a shared experience, and yet somehow we barely talk about what surviving cancer actually does to you.
